Entheon Biomedical (XCNQ:ENBI) Net Income From Continuing Operations : C$-0.32 Mil (TTM As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Entheon Biomedical's net income from continuing operations for the three months ended in Feb. 2024 was C$-0.08 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.32 Mil.

Entheon Biomedical Net Income From Continuing Operations Historical Data

The historical data trend for Entheon Biomedical's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Net Income From Continuing Operations Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-0.16

-0.15

-8.00

-2.06

-0.30

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.10	-0.04	-0.13	-0.08	-0.08

Entheon Biomedical Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.32 Mil.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines